KIYATEC to Present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
KIYATEC , the leader in clinically correlated, published functional precision oncology technology today announced that CEO Matt Gevaert, Ph.D., will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 1:30 PM Eastern Time.
- KIYATEC , the leader in clinically correlated, published functional precision oncology technology today announced that CEO Matt Gevaert, Ph.D., will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 1:30 PM Eastern Time.
- KIYATECs participation includes virtual one-on-one meetings with investors during the two-day event which begins Tuesday, March 22nd.
- Leveraging its innovative 3D cell culture technology platform for both clinical and pre-clinical use, KIYATEC recently introduced its first commercial assay in the US, 3D Predict Glioma.
- Recently, KIYATEC began a facilities expansion to support the Companys five-year growth plans to increase laboratory capacity and accelerate product development.